Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › tisotumab vedotin

tisotumab vedotin

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of tisotumab vedotin

4 trials tracked of tisotumab vedotin: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 146 citations.

4Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 1 Phase 2 3
  1. Phase 3 Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer Completed · 146 cited
  2. Phase 2 A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208) Completed
  3. Phase 2 Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors. Completed
  4. Phase 2 A Trial of Tisotumab Vedotin in Cervical Cancer Completed

Showing the 4 most-cited and recently-updated of 4 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Case report on sequential therapy for MET exon 14 skipping NSCLC with high PD-L1
Oncology Meta-analysis
Case report on sequential therapy for MET exon 14 skipping NSCLC with high PD-L1 A New Drug Sequence Shrank Lung Tumors When Others Failed
This is a case report with literature review of a 79-year-old male with MET exon 14 skipping non-small cell lung cancer and high PD-L1 expre…
A 79-year-old man's lung tumors shrank when doctors switched his drug sequence, offering a clue for others with hard-to-treat cancer.
Frontiers May 12, 2026
Precision oncology enables targeted therapies for gynecologic cancers, though acquired resistance remains a barrier
Oncology Sys. Review
Precision oncology enables targeted therapies for gynecologic cancers, though acquired resistance remains a barrier Precision oncology advances gynecologic cancer care but resistance remains a major barrier
This systematic review examined the current landscape of precision oncology for patients with endometrial, ovarian, and cervical carcinomas.
Molecular reclassification lets doctors use targeted drugs effectively for gynecologic cancers, but tumor evolution creates a major barrier …
Frontiers Apr 9, 2026